Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome

2013/01/28 by Z. E. Belaya, Zhanna Belaya, L. Y. Rozhinskaya +13
Medicine · #Bone health and osteoporosis research #Growth Hormone and Insulin-like Growth Factors #Pituitary Gland Disorders and Treatments

paper · doi:10.1007/s00198-013-2268-y

openalex publication_date 2013/01/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Citations

• The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
• Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss
• Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis
• Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing’s syndrome: A prospective, long-term study
• Increased risk of osteoporotic fractures in patients with Cushing's syndrome
• Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome
• Use of Oral Corticosteroids and Risk of Fractures